Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in mild to moderate COVID-19 pneumonia
NCT06847204Phase 2Completed
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colchicine in COVID-19 pneumonia (2 arms). Primary endpoints: Hospital stay at 7 days and Oxygen dependence at 7 days. Started Feb 2025; status: completed.
02
Drugs
colchicine
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT06847204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847204.